Cargando…

Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT(®) Re-usable Inhaler

BACKGROUND: RESPIMAT(®) re-usable enables patients to re-use the inhaler and its availability therefore reduces the number of inhalers and associated wastage. OBJECTIVE: The objective of this study was to perform an economic evaluation that incorporates the ecological impact of adopting RESPIMAT re-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortsäter, Gustaf, Borgström, Fredrik, Baldwin, Mike, Miltenburger, Carolin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250803/ https://www.ncbi.nlm.nih.gov/pubmed/31808066 http://dx.doi.org/10.1007/s40258-019-00540-0

Ejemplares similares

A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT(®) Re-usable in the Nordics and Benelux
por: Ortsäter, Gustaf, et al.
Publicado: (2019)

Reduced Environmental Impact of the Reusable Respimat(®) Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
por: Hänsel, Michaela, et al.
Publicado: (2019)

Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
por: Dhand, Rajiv, et al.
Publicado: (2019)

Patient perceptions of the re-usable Respimat(®) Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
por: Dreher, Michael, et al.
Publicado: (2021)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders
por: Dalby, Richard N, et al.
Publicado: (2011)

Budget impact analysis of the adoption of new hypertension guidelines in Colombia
por: Guevara-Cuellar, Cesar Augusto, et al.
Publicado: (2018)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Adoption of Initial Budget
Publicado: (1954)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

Clinical effectiveness of the Respimat(®) inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
por: Ram, Felix SF, et al.
Publicado: (2011)

Higher lung deposition with Respimat(®) Soft Mist(™) Inhaler than HFA-MDI in COPD patients with poor technique
por: Brand, Peter, et al.
Publicado: (2008)

In Vitro Determination of Respimat(®) Dose Delivery in Children: An Evaluation Based on Inhalation Flow Profiles and Mouth–Throat Models
por: Bickmann, Deborah, et al.
Publicado: (2016)

A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
por: Kamin, Wolfgang, et al.
Publicado: (2015)

Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat
por: Davis, Kimberly H., et al.
Publicado: (2017)

The impact of global budget on the diffusion of innovations: the example of positron emission tomography in Taiwan
por: Yang, Che-Ming
Publicado: (2018)

Procedure for the Adoption of the CERN Budget
Publicado: (1956)

Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
por: Rajesh, V., et al.
Publicado: (2020)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Assessment of Patient Experiences with Respimat(®) in Everyday Clinical Practice
por: Taube, Christian, et al.
Publicado: (2020)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies
por: Ichinose, Masakazu, et al.
Publicado: (2016)

Budget impact from the incorporation of positron emission tomography – computed tomography for staging lung cancers
por: Biz, Aline Navega, et al.
Publicado: (2015)

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
por: Anzueto, Antonio, et al.
Publicado: (2015)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015)

The potential impact of immunization campaign budget re-allocation on global eradication of paediatric infectious diseases
por: Fitzpatrick, Tiffany, et al.
Publicado: (2011)

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
por: Shah, Anshul, et al.
Publicado: (2021)

Adoption of RTS, S malaria vaccine for children younger than 5 years in Rwanda: A budget impact analysis
por: Ndikumukiza, Cyrille, et al.
Publicado: (2021)

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease
por: Aalbers, René, et al.
Publicado: (2015)

A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
por: Dahl, Ronald, et al.
Publicado: (2016)

Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients
por: Negro, Roberto Dal, et al.
Publicado: (2007)

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
por: Rau-Berger, Heike, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_oq0ffjj3uu39v26r0jiovb18up